Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 76
- Registration Number
- NCT01545947
- Locations
- 🇺🇸
NYU School of Medicine, New York, New York, United States
🇺🇸Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 12
- Registration Number
- NCT01522547
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine
- Conditions
- Interventions
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 34
- Registration Number
- NCT01519011
- Locations
- 🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸Moores UCSD Cancer Center MC-0987, La Jolla, California, United States
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 34
- Registration Number
- NCT01497093
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 169
- Registration Number
- NCT01478685
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Netherlands
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 255
- Registration Number
- NCT01476787
- Locations
- 🇺🇸
Local Institution - 53003, Southfield, Michigan, United States
🇺🇸Local Institution - 51103, Houston, Texas, United States
🇺🇸Local Institution - 51203, Dallas, Texas, United States
A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 33
- Registration Number
- NCT01474330
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 5
- Registration Number
- NCT01466725
- Locations
- 🇺🇸
Dermatology and Research, Dallas, Texas, United States
🇺🇸Advanced Pharma, CR, LLC, Miami, Florida, United States
🇺🇸University of Miami - Department of Dermatology, Miami, Florida, United States
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 51
- Registration Number
- NCT01456039
- Locations
- 🇯🇵
Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan
🇯🇵Sapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 271
- Registration Number
- NCT01421524
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey University, New Brunswick, New Jersey, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇺🇸Texas Oncology, PA - Dallas 75246, Dallas, Texas, United States